Note 5 - Fair Value Measurements (Details Textual) $ / shares in Units, $ in Thousands			1 Months Ended
	Jan. 07, 2025 USD ($) shares	Jan. 07, 2024 USD ($) $ / shares shares	Feb. 28, 2024	Mar. 31, 2010 USD ($) $ / shares	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Forward Contract Liabilities					$ 1,289	$ 3,129
Manhattan and Ariston Pharmaceuticals Merger [Member]
Notes Issued				$ 15,500
Debt Instrument, Term (Year)				5 years
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 1,125
Precision BioSciences, Inc. [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			30
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares) | shares	220,712	220,712
Investment Purchased Balance Price Per Share (in dollars per share) | $ / shares		$ 0.77
Payments to Acquire Equity Securities, FV-NI	$ 2,500
License Agreement, Payment, Percentage of Weighted Average Share Price	200.00%
License Agreement, Share Price, Trading Days (Day)	30 days
Equity Method Investments, Fair Value Disclosure	$ 1,400
Precision BioSciences, Inc. [Member] | Maximum [Member]
Investment Purchased Balance Shares (in shares) | shares		2,920,816
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront		$ 7,500
License Agreement, Amount Paid Upfront, Cash		5,250
License Agreement, Amount Paid Upfront, Equity Investment		$ 2,250
License Agreement, Payment, Percentage of Weighted Average Share Price		200.00%
License Agreement, Share Price, Trading Days (Day)		30 days
License Agreement, Milestone Stock Payment		$ 2,300
Forward Contract Liabilities					$ 1,300